High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy

Author： Balleine Rosemary L.   Wilcken Nicholas R.  

Publisher： Adis International

ISSN： 1177-1062

Source： Molecular Diagnosis & Therapy, Vol.16, Iss.4, 2012-08, pp. : 235-240

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Active smoking and the risk of estrogen receptor‐positive and triple‐negative breast cancer among women ages 20 to 44 years

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1026-1034

John Wiley & Sons Inc

Access to resources Recommend Favorite

Height, body mass index (BMI), BMI change, and the risk of estrogen receptor‐positive, HER2‐positive, and triple‐negative breast cancer among women ages 20 to 44 years

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1548-1556

John Wiley & Sons Inc

Access to resources Recommend Favorite

Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen

By  

Current Signal Transduction Therapy, Vol. 3, Iss. 1, 2008-01 ,pp. : 7-21

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 2, 2017-05 ,pp. : 67-72

Bentham Science Publishers

Access to resources Recommend Favorite

The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor‐positive breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 3, 2015-08 ,pp. : 686-697

John Wiley & Sons Inc

Access to resources Recommend Favorite